Axsome Therapeutics登记solriamfetol治疗儿童青少年ADHD的III期开放标签长期安全性研究（NCT07773883）
Axsome Therapeutics在ClinicalTrials.gov更新登记NCT07773883：一项III期、多中心、开放标签研究，评估solriamfetol在患ADHD（注意缺陷多动障碍）的儿童青少年中的长期安全性。本次材料仅提供方案描述，未报告招募状态、样本量、主要终点或安全性结果，具体状态以登记库后续提交为准。
#精神健康
ClinicalTrials.gov API v2 · 登记更新 EMA · What's New 欧盟撤回阿片依赖替代治疗药Suboxone（buprenorphine/naloxone）上市许可，企业以商业原因申请永久停售
2026年9月11日，欧洲委员会应上市许可持有人Indivior Europe Limited申请撤回Suboxone（buprenorphine/naloxone）在欧盟的上市许可，原因为企业出于商业考虑永久停售。
EMA · News and Safety Reviews精选 精神医学：Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 26 - 29 October 2026
原文摘录：Image credit: © tadamichi | stock.adobe.com Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 26 - 29 October 2026 30 October 2026 PRAC starts review of depression and anxiety medicine Deanxit and a safety signal related to hu … eu All other enquiries please submit your request via the online form Follow us on Bluesky Related medicine information Flupentixol/melitracen-containing medicinal products - referral Topics Pharmacovigilance
关注理由：如果关注精神医学，这篇内容值得阅读其研究对象、方法设计和主要发现。
Europe PMC · 撤稿与关系监测精选 精神医学：RETRACTED ARTICLE: Gatekeeping Mental Health Care: A Critical Analysis of mhGAP-HIG Implementation in Cameroon's Anglophone Crisis Through an Anti-Oppressive Lens.
原文摘录：Ndze, Y. E. (2026). Gatekeeping Mental Health Care: A Critical Analysis of mhGAP-HIG Implementation in Cameroon's Anglophone Crisis Through an Anti-Oppressive Lens. Journal of Evidence-Based Social Work , 1-33. https://doi.org/10.1080/26408066.2026. … The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as 'Retracted'
关注理由：这条精神医学资料涉及具体临床问题，研究人群、方法和结局指标可以结合原文进一步查看。